The EU approval adds a significant label expansion for Datroway, supporting AstraZeneca's oncology revenue growth. Monitor upcoming sales reports and label expansions in additional geographies (China, Japan) for further upside. The strong OS and PFS data may also support future guideline inclusion and pricing negotiations.
Price Chart
Executive Summary
AstraZeneca's Datroway (datopotamab deruxtecan) received EU approval as monotherapy for 1st-line metastatic triple-negative breast cancer (TNBC) in patients ineligible for immunotherapy, based on the TROPION-Breast02 Phase III trial showing a 5.0-month median overall survival improvement (23.7 vs 18.7 months, HR 0.79) and a 43% reduction in progression/death risk. This expands Datroway's EU label to two breast cancer indications and positions it as the only TROP2-directed ADC with an overall survival benefit in this setting, reinforcing AstraZeneca's oncology growth trajectory.
Key Facts
- EU approval for 1st-line metastatic TNBC in patients not candidates for PD-1/PD-L1 inhibitor therapy.
- Approval based on TROPION-Breast02 Phase III trial: median OS 23.7 months (Datroway) vs 18.7 months (chemotherapy); HR 0.79 (p=0.0291).
- Risk of disease progression or death reduced by 43% (HR 0.57; p<0.0001); ORR 62.5% vs 29.3%.
- Datroway now approved for two breast cancer indications in the EU (HR+/HER2- and TNBC).
- Previously approved in the US for same TNBC indication (May 2026); additional reviews ongoing in China, Japan, Australia, Canada, Singapore, Switzerland.
- Included in ESMO Clinical Practice Guidelines as Category IA 1st-line option; ESMO-MCBS score 4/5.
Financial Impact
EU approval expands addressable market for Datroway in TNBC, a disease with ~81,000 annual diagnoses in Europe. No specific revenue figures provided in the filing.
Risk Factors
- Competition from other TROP2-directed ADCs (e.g., Trodelvy) and emerging therapies in TNBC.
- Reimbursement and pricing negotiations across EU member states may limit commercial uptake.
- Continued approval in US for NSCLC indication contingent on confirmatory trial verification.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-007050 |
| Document: 0001654954-26-007050-index-headers.html | 0001654954-26-007050 |
| Document: 0001654954-26-007050-index.html | 0001654954-26-007050 |
| Document: 0001654954-26-007050.txt | 0001654954-26-007050 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $161.85 $168.37 | ▲ +4.03% | ▲ +1.90% | $156.93 (−3.04%) |
Sep 14, 2026 18d ago | 6-K | $163.78 $168.10 | ▼ −2.64% | ▼ −2.53% | $156.93 (+4.18%) |
Sep 8, 2026 24d ago | 6-K | $160.04 $161.85 | ▲ +1.13% | ▲ +2.25% | $156.93 (−1.94%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.93 (−3.26%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.93 (−3.26%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $156.93 (−3.41%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.93 (−3.26%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.93 (−3.26%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $156.93 (−3.41%) |
Aug 31, 2026 4w ago | Court Ruling | $162.13 $159.95 | ▲ +1.34% | ▲ +1.20% | $156.93 (+3.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access